Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

At steady state after twice-daily administration, C max increased dose proportionally over the entire dose range while the exposure in terms of AUC showed a trend to increase more than dose proportionally (Table 3 ).

also in 53,322 other papers

Including random effects on total plasma clearance and volume of distribution of both compounds (CL P / F , CL M / F , V C / F , and V M / F ) resulted in a highly significant change in NONMEM OFV of −5,664.

also in 132,142 other papers